Over 1150 Total Lots Up For Auction at Three Locations - WI 07/09, NJ Cleansweep 07/10, CA 07/11

New research supports clinical utility of iCAD's Breast AI Suite

Press releases may be edited for formatting or style | November 22, 2022 Artificial Intelligence Women's Health
NASHUA, N.H. – November 21, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new and real-world research demonstrating the value of its Breast AI Suite will be highlighted at the Radiological Society of North America (RSNA) Annual Meeting in Chicago, November 27 to December 1. The Company is also showcasing this technology in booth #4754 at the meeting.

“Leading institutions and experts continue to validate the benefits our Breast AI Suite offers to clinicians and patients alike, establishing our technology as the most widely adopted breast cancer detection solution worldwide,” said Stacey Stevens, President and CEO of iCAD, Inc. “At this year’s RSNA meeting, we are pleased to see the clinical utility of our solutions reflected in new research, adding to a growing body of evidence supporting our Breast AI Suite. Not only is our Breast AI Suite clinically proven to improve radiologists’ performance, but more importantly, it is uniquely enhancing patient care and improving lives.”

Study affirms utility of ProFound AI’s Case Scores in improving cancer detection
stats Advertisement
DOTmed text ad

Ensure critical devices are ready to go

Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.

stats Advertisement
In a digital poster discussion on Monday, November 28 from 9:00-9:30 am CST titled “Clinical Implications of Changes in Artificial Intelligence Software Case Scores from Prior to Current Digital Breast Tomosynthesis Screening Exam” (Session number: M2-SPBR), Emily F. Conant, MD, Professor and Chief, Division of Breast Imaging at the Hospital of the University of Pennsylvania Medical Center, will discuss her research evaluating the degree of change in ProFound AI® Case Scores over sequential screens relative to outcomes. Represented on a scale of 0 to 100%, Case Scores represent the algorithm’s relative confidence that a lesion is malignant. Study findings suggest radiologists using ProFound AI should consider changes in Case Scores over sequential screens, as larger increases may indicate an increased likelihood of screen-detected cancer.

ProFound AI increases rate of cancer detection by 27%

In an oral presentation on Monday, November 28 from 9:30-10:30 am CST, titled “Real World Clinical Impact of Implementing Artificial Intelligence on Radiologists’ Performance in High Volume Mammography Screening” (Session M3-SSBR03), Axel Gräwingholt, MD, Radiologie am Theater in Paderborn, Germany will present findings from a study that compared radiologist performance both before and after adopting ProFound AI for 2D Mammography. The study revealed ProFound AI helped radiologists detect 1.2 additional cancers per 1,000 women screened, which is a 27% increase in the rate of cancer detection, without significantly increasing the rate of abnormal interpretations.

You Must Be Logged In To Post A Comment